Market Exclusive

Analyst Activity – Cantor Fitzgerald Reiterates Overweight on Arena Pharmaceuticals (NASDAQ:ARNA)

Analyst Ratings For Arena Pharmaceuticals (NASDAQ:ARNA)

Today, Cantor Fitzgerald reiterated its Overweight rating on Arena Pharmaceuticals (NASDAQ:ARNA) with a price target of $37.00.

There are 3 hold ratings, 6 buy ratings on the stock.

The current consensus rating on Arena Pharmaceuticals (NASDAQ:ARNA) is Buy (Score: 2.67) with a consensus target price of $38.83 per share, a potential 59.94% upside.

Some recent analyst ratings include

Dividend information for Arena Pharmaceuticals (NASDAQ:ARNA)

.

Recent Trading Activity for Arena Pharmaceuticals (NASDAQ:ARNA)
Shares of Arena Pharmaceuticals closed the previous trading session at 24.30 up +0.02 0.08% with 1,180,562 shares trading hands.

Exit mobile version